2, R & D vigorously invested in hard to stop some of the operating indicators get worse, the substantial growth in sales revenue is also the result of the PuMenTech R & D investment. In the first half of this year, the amount of R & D investment in Pu Men science and technology is 42.62 million yuan, R & D investment accounted for the current operating income of 16.44%, compared with the same period last year, an increase of 0.5 percentage points.
3, the increase in R & D investment is brought about by a variety of scientific research results, in 2020, Pu Men science and technology added 2 new authorized patents, of which 1 invention patent; new computer software copyright certificate 4; new medical device registration certificate 10 and a class of medical devices for the record 9; to obtain the certificate of registration of scientific and technological achievements of a certificate; 25 new products to obtain the CE certification; new FDA certification 6 Glycated hemoglobin analyzer GH-900, H8, H9 and dry fluorescence immunoassay analyzer FA-160 and other 4 production testing equipment to obtain the International Federation of Clinical Chemistry (IFCC) certification and the U.S. Glycated Hemoglobin Standardization Program (NGSP) double certification.
4, from the beginning of this year, July 27 closing, Pu Gate Technology's share price rose 77.98%, the same period belonging to the industry sector rose 89.31%. It is worth noting that in the company released 2020 half-year report during the last two trading days, its share price fell sharply for two consecutive trading days, a total decline of 19.55%. Industry insiders believe that although the overall operating results of PuMen Technology has achieved significant growth, some of the company's operating indicators are getting worse, such as the company's inventory growth rate in the first half of the year was much higher than the growth rate of operating costs and the growth rate of operating income.